Drug Development for Obesity - a marcus evans conference - key strategies for effective drug discovery.
Collins
Tracey
T
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. tracey.collins@thomson.com
D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D005768:Gastrointestinal Hormones / Q000037:antagonists & inhibitors; D006801:Humans; D007028:Hypothalamic Hormones / Q000037:antagonists & inhibitors; D008543:Melanins / Q000037:antagonists & inhibitors; D024821:Metabolic Syndrome / Q000188:drug therapy; D009765:Obesity / Q000188:drug therapy* / Q000235:genetics; D010907:Pituitary Hormones / Q000037:antagonists & inhibitors; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
D019440:Anti-Obesity Agents; D005768:Gastrointestinal Hormones; D007028:Hypothalamic Hormones; D008543:Melanins; D010907:Pituitary Hormones; D043884:Receptor, Cannabinoid, CB1; D017366:Serotonin Receptor Agonists; C019463:melanin-concentrating hormone